<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527005</url>
  </required_header>
  <id_info>
    <org_study_id>UIbadan</org_study_id>
    <nct_id>NCT02527005</nct_id>
  </id_info>
  <brief_title>A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients</brief_title>
  <official_title>A Comparative Study of Azithromycin and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant HIV Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ibadan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ibadan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled single blind prospective comparative study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to be a randomized controlled single blind prospective comparative
      study conducted to compare the efficacy of three monthly doses of sulphadoxine-pyrimethamine
      as intermittent preventive therapy for malaria with azithromycin in HIV positive pregnant
      women
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of malaria parasitemia at delivery in HIV positive women following administration of Azithromycin or Sulphadoxine- pyrimethamine as intermittent preventive therapy for malaria in pregnancy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Malaria</condition>
  <condition>Pregnant</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tabs Azithromycin 500mg daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulphadoxine-pyrimethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphadoxine-pyrimethamine</intervention_name>
    <description>Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_label>Sulphadoxine-pyrimethamine</arm_group_label>
    <other_name>Vitadar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Tabs Azithromycin 500mg daily for 3 days</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_label>Sulphadoxine-pyrimethamine</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant HIV positive patients,

          -  Gestational age 16 weeks and above,

          -  No history of azithromycin or sulphadoxine-pyrimethamine use four weeks prior to
             recruitment

        Exclusion Criteria:

          -  Anaemia packed cell volume less than 30%,

          -  pre-existing medical conditions- diabetes mellitus,

          -  hypertension,

          -  allergy to sulphadoxine-pyrimethamine or azithromycin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AYODELE O AROWOJOLU, MBBS IBADAN</last_name>
    <role>Study Director</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ORIYOMI O AKINYOTU, MBBS IBADAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL, IBADAN, OYO STATE, NIGERIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ADENIKE F BELLO, MBBS IBADAN</last_name>
    <role>Study Director</role>
    <affiliation>UNIVERSITY COLLEGE HOSPITAL, IBADAN, OYO STATE, NIGERIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ADEOLA R ABDUS-SALAM, MBBS IBADAN</last_name>
    <role>Study Director</role>
    <affiliation>ADEOYO MATERNITY TEACHING HOSPITAL, IBADAN, OYO STATE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ORIYOMI O AKINYOTU, MBBS IBADAN</last_name>
    <phone>+2348035044590</phone>
    <email>oriyomiddoc@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ADENIKE F BELLO, MBBS IBADAN</last_name>
    <phone>+2348037084505</phone>
    <email>nikeoluyemi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College Hospital,</name>
      <address>
        <city>Ibadan</city>
        <state>Oyo</state>
        <zip>200001</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ORIYOMI O AKINYOTU, MBBS IBADAN</last_name>
      <phone>+2348035044590</phone>
      <email>oriyomiddoc@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>ADENIKE F BELLO, MBBS IBADAN</last_name>
      <phone>+2348037084505</phone>
      <email>nikeoluyemi@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999 Jan;28(1):74-81.</citation>
    <PMID>10028075</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 17, 2015</lastchanged_date>
  <firstreceived_date>August 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ibadan</investigator_affiliation>
    <investigator_full_name>ORIYOMI OMOTOYOSI AKINYOTU</investigator_full_name>
    <investigator_title>Senior Registrar</investigator_title>
  </responsible_party>
  <keyword>IPT</keyword>
  <keyword>malaria</keyword>
  <keyword>pregnant</keyword>
  <keyword>HIV positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
